{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EYLEA",
    "query": {
      "intervention": "EYLEA"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 267,
    "total_pages": 27,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EYLEA&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-23T18:51:15.884Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05407636",
      "title": "Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "AMD",
        "nAMD",
        "Wet Age-related Macular Degeneration",
        "wAMD",
        "WetAMD",
        "CNV"
      ],
      "interventions": [
        {
          "name": "ABBV-RGX-314 Dose 1",
          "type": "GENETIC"
        },
        {
          "name": "ABBV-RGX-314 Dose 2",
          "type": "GENETIC"
        },
        {
          "name": "Aflibercept (EYLEA®)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "BIOLOGICAL"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "50 Years to 89 Years"
      },
      "enrollment_count": 735,
      "start_date": "2022-01-13",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-09-23T18:51:15.884Z",
      "location_count": 107,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05407636"
    },
    {
      "nct_id": "NCT02462889",
      "title": "IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Intravitreal aflibercept injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jeffrey S Heier",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 128,
      "start_date": "2015-06",
      "completion_date": "2019-03",
      "has_results": true,
      "last_update_posted_date": "2025-11-14",
      "last_synced_at": "2026-09-23T18:51:15.884Z",
      "location_count": 4,
      "location_summary": "Beverly Hills, California • Boston, Massachusetts • Edison, New Jersey + 1 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Edison",
          "state": "New Jersey"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02462889"
    },
    {
      "nct_id": "NCT02689518",
      "title": "EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Macular Degeneration",
        "Wet Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Intravitreal aflibercept injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 50,
      "start_date": "2014-04",
      "completion_date": "2019-11-12",
      "has_results": true,
      "last_update_posted_date": "2021-03-25",
      "last_synced_at": "2026-09-23T18:51:15.884Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02689518"
    },
    {
      "nct_id": "NCT02401945",
      "title": "A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "DE-120",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2015-04",
      "completion_date": "2016-10-31",
      "has_results": false,
      "last_update_posted_date": "2018-04-18",
      "last_synced_at": "2026-09-23T18:51:15.884Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Walnut Creek, California + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Golden",
          "state": "Colorado"
        },
        {
          "city": "Altamonte Springs",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02401945"
    },
    {
      "nct_id": "NCT02418754",
      "title": "Study of Intravitreal REGN2176-3 in Participants With Neovascular (\"Wet\") Age-Related Macular Degeneration (AMD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "REGN2176-3",
          "type": "DRUG"
        },
        {
          "name": "Intravitreal Aflibercept Injection (IAI)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 505,
      "start_date": "2015-05-05",
      "completion_date": "2017-04-03",
      "has_results": true,
      "last_update_posted_date": "2020-10-26",
      "last_synced_at": "2026-09-23T18:51:15.884Z",
      "location_count": 75,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 72 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02418754"
    },
    {
      "nct_id": "NCT00284141",
      "title": "Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Diseases",
        "Neoplasms, Lung"
      ],
      "interventions": [
        {
          "name": "Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2006-01",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2012-12-10",
      "last_synced_at": "2026-09-23T18:51:15.884Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00284141"
    },
    {
      "nct_id": "NCT04684394",
      "title": "A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration",
        "Retinal Disease",
        "Retinal Degeneration",
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "GEM103",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        },
        {
          "name": "Sham",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Gemini Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2020-12-29",
      "completion_date": "2022-02-18",
      "has_results": true,
      "last_update_posted_date": "2022-10-31",
      "last_synced_at": "2026-09-23T18:51:15.884Z",
      "location_count": 23,
      "location_summary": "Phoenix, Arizona • Campbell, California • Encino, California + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04684394"
    },
    {
      "nct_id": "NCT00436501",
      "title": "VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Malignant Tumor of Peritoneum",
        "Recurrent Ovarian Epithelial Cancer"
      ],
      "interventions": [
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "ziv-aflibercept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 58,
      "start_date": "2007-01",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2019-02-26",
      "last_synced_at": "2026-09-23T18:51:15.884Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • Charlottesville, Virginia",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00436501"
    },
    {
      "nct_id": "NCT01661972",
      "title": "Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Capecitabine and aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "John Strickler, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2012-08",
      "completion_date": "2016-06-12",
      "has_results": true,
      "last_update_posted_date": "2018-10-29",
      "last_synced_at": "2026-09-23T18:51:15.884Z",
      "location_count": 2,
      "location_summary": "Durham, North Carolina • Norfolk, Virginia",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01661972"
    },
    {
      "nct_id": "NCT00509795",
      "title": "Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "ranibizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aflibercept injection (VEGF Trap-Eye, BAY86-5321)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 1217,
      "start_date": "2007-08",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2012-12-28",
      "last_synced_at": "2026-09-23T18:51:15.884Z",
      "location_count": 176,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00509795"
    }
  ]
}